Scholar Rock Issues 83,102 Inducement Shares to Ten New Hires

Scholar Rock (NASDAQ: SRRK) has disclosed the issuance of new equity awards to ten recently hired employees. The company granted a total of 83,102 shares of common stock, split between 23,801 inducement stock options and 59,301 restricted stock units (RSUs). These grants were executed under the company's 2022 Inducement Equity Plan, which is specifically designed to recruit talent from outside the organization or from individuals who have been out of employment for a bona fide period.

The stock options carry an exercise price of $51.85, a figure matched to the closing price of Scholar Rock’s common stock on September 14, 2026. According to the disclosure reported by Yahoo Finance, this pricing mechanism ensures the grants are market-rate instruments rather than discounted equity. The awards are contingent on the recipients maintaining their employment with the company through the respective vesting dates, tying long-term retention directly to equity ownership.

Vesting schedules align with retention goals

The vesting structure for the stock options is designed to phase in over four years. Twenty-five percent of the underlying shares vest on the first anniversary of each employee’s start date. The remaining 75% vest in twelve equal quarterly installments over the subsequent three years. This staggered approach locks in key personnel during the critical initial period of their tenure.

In contrast, the 59,301 RSUs vest in four equal annual installments. This simpler schedule provides a steady accumulation of equity value for the new hires. All vesting events are strictly conditioned on continuing service, meaning any departure prior to the vesting date results in the forfeiture of unvested awards. This structure aligns the financial interests of the new employees with the long-term performance of the company.

Recruitment under Nasdaq listing rules

These grants were issued pursuant to Nasdaq Listing Rule 5635(c)(4), which permits issuers to grant inducement awards to new hires without shareholder approval. The rule is intended to facilitate the recruitment of essential personnel who are not currently shareholders. Scholar Rock’s board adopted the 2022 Inducement Equity Plan on June 16, 2022, to provide a compliant framework for such hires.

The plan restricts grants to individuals who were not previously employees of Scholar Rock, or who have been out of employment for a bona fide period. This ensures that the equity serves as a genuine inducement to join the company rather than a retention tool for existing staff. The company maintains that this mechanism is critical for accessing specialized talent in the biopharmaceutical sector.

Context of current business operations

Scholar Rock is focused on commercializing ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA). The company is preparing for global launch, beginning in the United States for patients aged two and older who are currently receiving SMN2-targeted treatments. The recruitment of new employees likely supports the scaling of commercial and operational infrastructure necessary for this rollout.

As a leader in myostatin biology, Scholar Rock utilizes a proprietary platform to develop monoclonal antibodies that modulate protein growth factors. The equity grants are part of a broader strategy to build a workforce capable of advancing these novel treatment approaches. The company continues to target rare neuromuscular diseases where muscle atrophy remains a significant unmet medical need.